8 June 2016 - This marks the first approval for Avastin in combination with another targeted therapy.

Roche announced today that the European Commission has approved the use of Avastin (bevacizumab) in combination with Tarceva (erlotinib hydrochloride) for the first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor activating mutations.

For more details, go to: http://www.roche.com/media/store/releases/med-cor-2016-06-08.htm